Signature of a license agreement between 4P-Pharma, SATT-Aquitaine and University of Bordeaux for the development of an anti-cancer drug.
Talence, September 1st
4P-Pharma has signed an exclusive license agreement with Aquitaine Science Transfert, for the development of a drug targeting pancreatic cancer, triple negative breast cancer or colon cancer. The molecule was first developed and patented by researchers from the laboratory of Angiogenesis and Cancer Microenvironment (LAMC – University of Bordeaux / Inserm).This signature materializes the technology transfer process managed by Inserm Transfert and the SATT Aquitaine. The funding for the project maturation amounts to 375 k€ over a 3-year time frame.
Read the full press release :
EN: Press Release 4P-Pharma SATT Aquitaine License agreement
FR: Communiqué de presse 4P Pharma-SATT Aquitaine 2016
Watch the video of the event
Press contact Aquitaine Science Transfert
Claire Moras, communications manager
E-Mail : firstname.lastname@example.org. Phone : 33 (0)5 33 51 43 28 . Cell: 06 19 57 48 66 .
Yann Mondon, marketing and communications director.
E-Mail : email@example.com. Phone : +33 (0)6 30 51 22 94 . Cell : 06 30 51 22 94 .
Press contact 4P-Pharma
Keren Bismuth, scientific communications manager.
E-mail: firstname.lastname@example.org. Phone :33 (0)9 72 84 72 64.